Subscribe to Newsletter
Subspecialties Retina, Basic & Translational Research

White Out

Researchers at the National Eye Institute (NEI) believe that nitisinone may increase melanin production in people with oculocutaneous albinism type 1B (OCA-1B). Patients with OCA-1B experience decreased visual acuity, glare sensitivity and, in many cases, nystagmus, which further degrades image quality.

OCA-1B is the most common form of albinism in the USA and it is characterized by a mutation in the gene that codes for tyrosinase. Tyrosinase breaks down the amino acid tyrosine and is the first enzyme in the pathway to melanin.  

But what is it that makes melanin so important to the development of normal vision? “The truth is we really don’t know,” says Brian Brooks, clinical director at the NEI and lead author of the study.

“There is something – likely something indirect – about the process of making melanin that can also affect the development of the cells of the retina. What’s particularly odd is that the cells of the retina where we see developmental abnormalities clinically do not express the genes for making melanin. It’s the neighboring retinal pigment epithelium and the melanocytes of the choroid that make the melanin,” he explains.

“A fair amount of excellent work has focused on the role of L-DOPA, which is an intermediate in the process of melanin production, which can exert some developmental effects on the retina – but that’s just part of the story.”

Though the team was unable to detect significant changes to melanin production or VA, they remain hopeful that nitisinone could benefit patients with OCA-1B.

In an attempt to find out more, the pilot study followed three women and two men with OCA-1B over 18 months. Each patient was given a two milligram oral dose of nitisinone every day for 12 months, along with six additional months without the drug. Why nitisinone?

“We know from basic biochemistry that one way to stabilize an enzyme is to increase the amount of its starting material or substrate. Nitisinone blocks the degradation of tyrosine, which has the side effect of raising its plasma levels. So, we are using a known side effect of this medication to flood the unstable tyrosinase enzyme with lots of tyrosine (substrate), making it more stable.”

The results? Most participants experienced a slight darkening of skin and hair, and one participant experienced a slight darkening in skin color after sun exposure. Though the team was unable to detect clinically significant changes to melanin production or visual acuity, Brooks remains hopeful that nitisinone could benefit patients with OCA-1B.

“We’re confident for a couple of reasons. One, we saw the effect in mice and, two, it is not uncommon for younger patients to have more ‘plasticity’ in their visual systems. In our pilot study, the patient who showed the most change in his skin and hair melanin was on the younger side,” he explains.

“That being said, I don’t suggest ophthalmologists prescribe nitisinone to their patients with albinism outside of a well-monitored and controlled clinical trial,” warns Brooks. “Although we did not see any serious adverse events in our pilot study, nitisinone can have significant side effects and patients need to be regularly monitored while they are on it.”

Brooks and his team hope to build on this research by running the trial with younger patients. They also hope to look into nitisinone’s efficacy on other forms of albinism.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. D Adams et al., “One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B”, JCI Insight, 4, 2 (2019). PMID: 30674731.
About the Author
Phoebe Harkin

Associate Editor of The Ophthalmologist

I’ve always loved telling stories. So much so, I decided to make a job of it. I finished a Masters in Magazine Journalism and spent three years working as a creative copywriter before itchy feet sent me (back)packing. It took seven months and 13 countries, but I’m now happily settled on The Ophthalmologist, where I’m busy getting stuck into all things eyeballs.

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: